Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04434196
Title A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Celgene
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ESP | CAN | AUT

Facility Status City State Zip Country Details
Local Institution - 106 Boston Massachusetts 02215 United States Details
Local Institution - 104 Columbus Ohio 43210 United States Details
Local Institution - 101 Portland Oregon 97201-3098 United States Details
Local Institution - 107 Dallas Texas 75390 United States Details
Local Institution - 403 Innsbruck 6020 Austria Details
Local Institution - 401 Salzburg 5020 Austria Details
Local Institution - 402 Wien 1090 Austria Details
Local Institution - 201 Toronto Ontario M5G 2M9 Canada Details
Local Institution - 202 Montreal Quebec H3T 1E2 Canada Details
Local Institution - 302 Barcelona 08035 Spain Details
Local Institution - 306 Madrid 28027 Spain Details
Local Institution - 301 Madrid 28041 Spain Details
Local Institution - 304 Pamplona 31008 Spain Details
Local Institution - 303 Salamanca 37007 Spain Details
Local Institution - 305 Valencia 46010 Spain Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field